Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer

European Urology, Supplements

Volumn 7, Issue 10, 2008, Pages 651-666

  Lamm, Donald ^a   Colombel, Marc ^b   Persad, Raj ^c   Soloway, Mark ^d   Böhle, Andreas ^e   Palou, Joan ^f   Witjes, J Alfred ^g   Akaza, Hideyuki ^h   Buckley, Roger ⁱ   Brausi, Maurizio ^j  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITÉ LYON 1   (France)

^c BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e HELIOS AGNES KARLL HOSPITAL   (Germany)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF TSUKUBA   (Japan)

ⁱ NORTH YORK GENERAL HOSPITAL   (Canada)

^j AUSL Modena   (Italy)

more..

Author keywords

Bacillus Calmette Gu rin; Follow up of non muscle invasive bladder cancer; Intravesical chemotherapy; Management of non muscle invasive bladder cancer; Management of recurrences; Management of treatment failures; Post operative chemotherapeutic instillation; Recommendations; Transurethral resection of the bladder tumour

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; ISONIAZID; MITOMYCIN C; THIOTEPA;

BLADDER CANCER; CALCINOSIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CYSTECTOMY; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAINTENANCE THERAPY; MEDICAL LITERATURE; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; TRANSURETHRAL RESECTION; TREATMENT FAILURE;

EID: 51549088346     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.07.009     Document Type: Review

References (72)

1. Burnand K., Boyd P., Mayo M., Shuttleworth K.E., and Lloyd-Davies R.W. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder cancer. Br J Urol 48 (1976) 55-59
2. Garrett J., Lewis R., Meehan W., et al. Intravesical thiotepa in the immediate post-operative period in patients with recurrent transitional cell carcinoma of the bladder. J Urol 120 (1978) 410-411
3. Sylvester R.J., Oosterlinck W., and Witjes J.A. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 53 (2008) 709-719
4. Coe J.E., and Feldman J.D. Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology 10 (1966) 127-136
5. Silverstein M.J., DeKernion J., and Morton D.L. Malignant melanoma metastatic to the bladder: regression following intratumor injection of BCG vaccine. JAMA 229 (1974) 688
6. deKernion J.B., Golub S.H., Gupta R.K., Silverstein M., and Morton D.L. Successful transurethral intralesional BCG therapy of a bladder melanoma. Cancer 36 (1975) 1662-1667
7. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180-183
8. Lamm D.L., Thor D.E., Harris S.C., Reyna J.A., Stogdill V.D., and Radwin H.M. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 124 (1980) 38-40
9. Pinsky C.M., Camacho F.J., Kerr D., et al. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep 69 (1985) 47-53
10. Akaza H., Hinotsu S., Aso Y., Kakizoe T., and Koiso K. Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 75 (1995) 552-559
11. Akaza H., Koiso K., Ozono S., et al. A clinical study of PMCJ-9 (bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jap J Clin Oncol 33 (2003) 382-390
12. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J. European Association of Urology guidelines on TaT1 (non-muscle invasive) bladder cancer. Update March 2008. Arnhem, the Netherlands: European Association of Urology; 2008. http://www.uroweb.org/fileadmin/tx_eauguidelines/TaT1%20Bladder%20Cancer .pdf.
13. In: Soloway M.S. (Ed). International consultation on bladder tumours. Urology 66 Suppl 1 (2005) 1-125
14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer including upper tract tumours and urothelial carcinoma of the prostate. Version 1. Jenkintown, PA: NCCN; 2007.
15. American Urological Association. Guidelines for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. Linthicum, MD: AUA; 2007. http://www.auanet.org/guidelines/bladcan07.cfm.
16. Hall M.C., Chang S.S., Dalbagni G., et al. Guidelines for the management of non-muscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178 (2007) 2314-2330
17. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumours of the bladder: international consensus panel. Urology 66 Suppl 1 (2005) 108-125
18. Oosterlinck W., Solsona E., Akaza H., et al. Low-grade Ta (non-invasive) urothelial carcinoma of the bladder. Urology 66 Suppl 1 (2005) 75-89
19. Sylvester R.J., van der Meijden A.P., Witjes J.A., et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66 Suppl 1 (2005) 90-107
20. Herr H.W. High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumour. Semin Urol Oncol 15 (1997) 142-146
21. Brausi M., Collette L., Kurth K., et al., EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
22. Sylvester R.J., Oosterlinck W., and van der Meijden A. A single immediate post-operative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
23. Kaasinen E., Rintala E., Hellström P., et al., FinnBladder Group. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42 (2002) 167-174
24. Oddens J.R., van der Meijden A.P., and Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?. Eur Urol 46 (2004) 336-338
25. Heney N.M., Koontz W.W., Barton B., et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol 140 (1988) 1390-1393
26. Hayek OR, Vita RR, Lucon MR, et al. Bladder perforation incidence in a consecutive series of transurethral bladder tumor resections performed by urology residents. Paper presented at: Annual Meeting of the American Urological Association; May 19-24, 2007; Anaheim, CA, USA.
27. Thrasher J.B., and Crawford E.D. Complications of intravesical chemotherapy. Urol Clin North Am 19 (1992) 529-539
28. Ali-el-Dein B., el-Baz M., Aly A.N., et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumours (stages pTa and pT1): a randomized prospective study. J Urol 158 (1997) 68-73
29. Hendricksen K., Witjes W.P., Idema J.G., et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 53 (2008) 984-991
30. Witjes J.A., and Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53 (2008) 45-52
31. McKiernan J.M., Masson P., Murphy A.M., et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24 (2006) 3075-3080
32. Lamm D.L., Riggs D.R., Traynelis C.L., et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153 (1995) 1444-1450
33. Millan-Rodriguez F., Chéchile-Toniolo G., Salvador-Bayarri J., Palou J., and Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163 (2000) 73-78
34. Pawinski A., Sylvester R., Bouffioux C., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156 (1996) 1934-1940
35. Hinotsu S., Akaza H., Ohashi Y., et al. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86 (1999) 1818-1826
36. Tolley D.A., Parmar M.K., Krigor K.M., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155 (1996) 1233-1238
37. Shelley M.D., Wilt T.J., Court J., Coles B., Kynaston H., and Mason M.D. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93 (2004) 485-490
38. Huncharek M., and Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder. Am J Clin Oncol 26 (2003) 402-407
39. Sylvester R.J., van der Meijden, and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
40. Sylvester R.J., Brausi M.A., Hoelti W., et al. Long-term efficacy results of EORTC GU Group study 30911 comparing epirubicin, bacillus Calmette-Guérin (BCG), and BCG plus isoniazid in patients with intermediate and high risk stage Ta T1 papillary carcinoma of the bladder. Eur Urol Suppl 7 (2008) 298
41. Bouffioux C., Kurth K., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153 (1995) 934-941
42. Nomata K., Noguchi M., Kanetake M., et al., Nagasaki Clinical Research Group for Bladder Cancer. Intravesical adjuvant chemotherapy for superficial transitional bladder cancer: results of a randomised trial with epirubicin comparing short and long-term maintenance treatment. Cancer Chemother Pharmacol 5 (2002) 266-270
43. Koga G., Kuroiwa K., Yamaguchi A., Osada Y., Tsuneyoshi M., and Naito S. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 171 (2004) 153-157
44. Böhle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
45. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
46. Böhle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 63 (2004) 682-686
47. Martinez-Pineiro J.A., Flores N., Isorna S., et al., CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89 (2002) 671-680
48. Martinez-Pineiro J.A., Martinez-Pineiro L., Solsona E., et al., CUETO (Club Urologico Espanol de Tratamiento Oncologico). Has a 3-fold decreased dose of bacillus Calmette-Guérin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174 (2005) 1242-1247
49. Ojea A., Nogueira J.L., Solsona E., et al., CUETO Group (Club Urológico Español De Tratamiento Oncológico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 52 (2007) 1398-1406
50. Hendricksen K., and Witjes J.A. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr Opin Urol 17 (2007) 352-357
51. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49 (2006) 790-797
52. Pansadoro V., and De Paula F. Intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder. J Urol 138 (1987) 299-301
53. Coplen D.E., Marcus M.D., Myers J.A., Ratliff T.L., and Catalona W.J. Long-term follow-up of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guérin: analysis of possible predictors of response free of tumour. J Urol 144 (1990) 652-657
54. Cookson M.S., and Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol 148 (1992) 797-801
55. Brake M., Loertzer H., Horsch R., and Keller H. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer. Urology 55 (2000) 673-678
56. Herr H.W., and Dalbagni G. Defining bacillus Calmette-Guérin refractory superficial bladder tumours. J Urol 169 (2003) 1706-1708
57. Stockle M., Alken P., Engelmann U., Jacobi G.H., Riedmiller H., and Hohenfellner R. Radical cystectomy-often too late?. Eur Urol 13 (1987) 361-367
58. Bochner B.H., Herr H.W., and Reuter V.E. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166 (2001) 2295-2296
59. Kim J.C., and Steinberg G.D. The limits of bacillus Calmette-Guérin for carcinoma in situ of the bladder. J Urol 165 (2001) 745-756
60. Bianco Jr. F.J., Justa D., Grignon D.J., Sakr W.A., Pontes J.E., and Wood Jr. D.P. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22 (2004) 290-294
61. Schrier B.P., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and possible implications for therapy. Eur Urol 45 (2004) 292-296
62. Denzinger S., Fritsche H.M., Otto W., Blana A., Wieland W.F., and Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 53 (2008) 146-152
63. Herr H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19 (2001) 89-93
64. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2008 Feb 22; [Epub ahead of print].
65. Steinberg G., Bahnson R., Brosman S., Middleton R., Wajsman Z., Wehle M., and The Valrubicin Study Group. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guérin refractory carcinoma in situ of the bladder. J Urol 163 (2000) 761-767
66. Newling D.W., Hetherington J., Sundaram S.K., Robinson M.R., and Kisbenedek L. The use of valrubicin for the chemoresection of superficial bladder cancer: a marker lesion study. Eur Urol 39 (2001) 643-647
67. Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin refractory transitional cell carcinoma of the bladder. J Clin Oncol 20 (2002) 3193-3198
68. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24 (2006) 2729-2734
69. Gontero P., Casetta G., Maso G., et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46 (2004) 339-343
70. O'Donnell M.A., Lilli K., and Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alfa-2b for superficial bladder cancer. J Urol 172 (2004) 888-893
71. O'Donnell M.A., Krohn J., and DeWolf W.C. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed. J Urol 166 (2001) 1300-1304
72. Joudi F.N., Smith B.J., O'Donnell M.A., and National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24 (2006) 344-348